Acute Leukemia in the Crosshairs: First‐in‐Class Menin Inhibitor Approval for Adults and Children

Pediatric Blood & CancerEarly View e31657 COMMENTARY Acute Leukemia in the Crosshairs: First-in-Class Menin Inhibitor Approval for Adults and Children Joanna S. Yi, Corresponding Author Joanna S. Yi [email protected] orcid.org/0000-0002-0914-8728 Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, USA Correspondence: Joanna S. Yi ([email protected])Search for more papers by this authorBranko Cuglievan, Branko Cuglievan Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this author Joanna S. Yi, Corresponding Author Joanna S. Yi [email protected] orcid.org/0000-0002-0914-8728 Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, USA Correspondence: Joanna S. Yi ([email protected])Search for more papers by this authorBranko Cuglievan, Branko Cuglievan Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this author First published: 18 March 2025 https://doi.org/10.1002/pbc.31657Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechat No abstract is available for this article. References 1B. Cuglievan, H. Kantarjian, J. E. Rubnitz, et al., "Menin Inhibitors in Pediatric Acute Leukemia: A Comprehensive Review and Recommendations to Accelerate Progress in Collaboration With Adult Leukemia and the International Community," Leukemia 38, no. 10 (2024): 2073–2084. Google Scholar 2G. C. Issa, I. Aldoss, J. DiPersio, et al., "The Menin Inhibitor Revumenib in KMT2A-Rearranged or NPM1-Mutant Leukaemia," Nature 615, no. 7954 (2023): 920–924. Google Scholar 3G. C. Issa, I. Aldoss, M. J. Thirman, et al., "Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)," Journal of Clinical Oncology (2024): JCO2400826. Google Scholar 4E. B. Heikamp, J. A. Henrich, F. Perner, et al., "The Menin-MLL1 Interaction Is a Molecular Dependency in NUP98-Rearranged AML," Blood 139, no. 6 (2022): 894–906. Google Scholar 5A. Attarbaschi, A. Moricke, C. J. Harrison, et al., "Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia with 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study," Journal of Clinical Oncology 41, no. 7 (2023): 1404–1422. Google Scholar 6J. Stutterheim, P. de Lorenzo, I. M. van der Sluis, et al., "Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukaemia Treated on the Interfant-06 Protocol," European Journal of Cancer 160 (2022): 72–79. Google Scholar 7G. Richard-Carpentier, H. M. Kantarjian, G. Tang, et al., "Outcomes of Acute Lymphoblastic Leukemia With KMT2A (MLL) Rearrangement: The MD Anderson Experience," Blood Advances 5, no. 23 (2021): 5415–5419. Google Scholar 8B. V. Balgobind, S. C. Raimondi, J. Harbott, et al., "Novel Prognostic Subgroups in Childhood 11q23/MLL-Rearranged Acute Myeloid Leukemia: Results of an International Retrospective Study," Blood 114, no. 12 (2009): 2489–2496. Google Scholar 9J. A. Pollard, E. Guest, T. A. Alonzo, et al., "Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results from the Phase III Children's Oncology Group Trial AAML0531," Journal of Clinical Oncology 39, no. 28 (2021): 3149–3160. Google Scholar 10G. C. Issa, F. Ravandi, C. D. DiNardo, E. Jabbour, H. M. Kantarjian, and M. Andreeff, "Therapeutic Implications of Menin Inhibition in Acute Leukemias," Leukemia 35, no. 9 (2021): 2482–2495. Google Scholar 11G. C. Issa, J. Zarka, K. Sasaki, et al., "Predictors of Outcomes in Adults With Acute Myeloid Leukemia and KMT2A Rearrangements," Blood Cancer Journal 11, no. 9 (2021): 162. Google Scholar 12C. Meyer, P. Larghero, B. Almeida Lopes, et al., "The KMT2A Recombinome of Acute Leukemias in 2023," Leukemia 37, no. 5 (2023): 988–1005. Google Scholar 13D. V. Wenge and S. A. Armstrong, "The Future of HOXA- expressing Leukemias: Menin Inhibitor Response and Resistance," Current Opinion in Hematology 31, no. 2 (2024): 64–70. Google Scholar 14F. Ostronoff, M. Othus, R. B. Gerbing, et al., "NUP98/NSD1 and FLT3/ITD Coexpression Is More Prevalent in Younger AML Patients and Leads to Induction Failure: A COG and SWOG Report," Blood 124, no. 15 (2014): 2400–2407. Google Scholar 15N. A. McNeer, J. Philip, H. Geiger, et al., "Genetic Mechanisms of Primary Chemotherapy Resistance in Pediatric Acute Myeloid Leukemia," Leukemia 33, no. 8 (2019): 1934–1943. Google Scholar 16H. Bolouri and J. E. Farrar, "The Molecular Landscape of Pediatric Acute Myeloid Leukemia Reveals Recurrent Structural Alterations and Age-Specific Mutational Interactions," Nature Medicine 24, no. 1 (2018): 103–112. Google Scholar 17N. L. Michmerhuizen, J. M. Klco, and C. G. Mullighan, "Mechanistic Insights and Potential Therapeutic Approaches for NUP98-Rearranged Hematologic Malignancies," Blood 136, no. 20 (2020): 2275–2289. Google Scholar 18G. G. Wang, L. Cai, M. P. Pasillas, and M. P. Kamps, "NUP98-NSD1 links H3K36 Methylation to Hox-A Gene Activation and Leukaemogenesis," Nature Cell Biology 9, no. 7 (2007): 804–812. Google Scholar 19C. G. Mullighan, A. Kennedy, X. Zhou, et al., "Pediatric Acute Myeloid Leukemia With NPM1 Mutations Is Characterized by a Gene Expression Profile With Dysregulated HOX Gene Expression Distinct From MLL-Rearranged Leukemias," Leukemia 21, no. 9 (2007): 2000–2009. Google Scholar 20L. Brunetti, M. C. Gundry, D. Sorcini, et al., "Mutant NPM1 Maintains the Leukemic State Through HOX Expression," Cancer Cell 34, no. 3 (2018): 499–512. e499. Google Scholar 21M. W. Kuhn, E. Song, Z. Feng, et al., "Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia," Cancer Discovery 6, no. 10 (2016): 1166–1181. Google Scholar 22J. Grembecka, S. He, A. Shi, et al., "Menin-MLL Inhibitors Reverse Oncogenic Activity of MLL Fusion Proteins in Leukemia," Nature Chemical Biology 8, no. 3 (2012): 277–284. Google Scholar 23A. A. Ferrando, S. A. Armstrong, D. S. Neuberg, et al., "Gene Expression Signatures in MLL-rearranged T-lineage and B-precursor Acute Leukemias: Dominance of HOX Dysregulation," Blood 102, no. 1 (2003): 262–268. Google Scholar 24A. V. Krivtsov, K. Evans, J. Y. Gadrey, et al., "A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia," Cancer Cell 36, no. 6 (2019): 660–673. e611. Google Scholar 25W. Fiskus, N. Daver, S. Boettcher, et al., "Activity of Menin Inhibitor ziftomenib (KO-539) as Monotherapy or in Combinations Against AML Cells With MLL1 Rearrangement or Mutant NPM1," Leukemia 36, no. 11 (2022): 2729–2733. Google Scholar 26M. C. Kwon, J. W. Thuring, O. Querolle, et al., "Preclinical Efficacy of the Potent, Selective Menin-KMT2A Inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered Leukemias," Blood 144, no. 11 (2024): 1206–1220. Google Scholar 27V. Ciaurro, A. Skwarska, N. Daver, and M. Konopleva, "Menin Inhibitor DS-1594b Drives Differentiation and Induces Synergistic Lethality in Combination With Venetoclax in AML Cells With MLL-Rearranged and NPM1 Mutation," Abstract presented at American Society of Hematology Annual Meeting 2022, New Orleans, LA, November 15, 2022. Google Scholar 28S. Klossowski, H. Miao, K. Kempinska, et al., "Menin Inhibitor MI-3454 Induces Remission in MLL1-rearranged and NPM1-Mutated Models of Leukemia," Journal of Clinical Investigation 130, no. 2 (2020): 981–997. Google Scholar 29H. J. Uckelmann, S. M. Kim, E. M. Wong, et al., "Therapeutic Targeting of Preleukemia Cells in a Mouse Model of NPM1 Mutant Acute Myeloid Leukemia," Science 367, no. 6477 (2020): 586–590. Google Scholar 30E. B. Heikamp, C. Martucci, J. A. Henrich, et al., "NUP98 fusion Proteins and KMT2A-MENIN Antagonize PRC1.1 to Drive Gene Expression in AML," Cell Reports 43, no. 11 (2024): 114901. Google Scholar 31M. Rasouli, H. Blair, S. Troester, et al., "The MLL-Menin Interaction Is a Therapeutic Vulnerability in NUP98-rearranged AML," Hemasphere 7, no. 8 (2023): e935. Google Scholar 32E. S. Wang, G. C. Issa, H. P. Erba, et al., "Ziftomenib in Relapsed or Refractory Acute Myeloid Leukaemia (KOMET-001): A Multicentre, Open-Label, Multi-cohort, Phase 1 Trial," Lancet Oncology 25, no. 10 (2024): 1310–1324. Google Scholar 33J. M. Barajas, M. Rasouli, M. Umeda, et al., "Acute Myeloid Leukemias With UBTF Tandem Duplications Are Sensitive to Menin Inhibitors," Blood 143, no. 7 (2024): 619–630. Google Scholar 34J. D. Sandahl, E. A. Coenen, E. Forestier, et al., "t(6;9)(p22;q34)/DEK-NUP214-rearranged Pediatric Myeloid Leukemia: An International Study of 62 Patients," Haematologica 99, no. 5 (2014): 865–872. Google Scholar 35I. M. van der Sluis, P. de Lorenzo, R. S. Kotecha, et al., "Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia," New England Journal of Medicine 388, no. 17 (2023): 1572–1581. Google Scholar 36S. Gupta, R. E. Rau, J. A. Kairalla, et al., "Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children," New England Journal of Medicine (2024). Google Scholar 37M. R. Litzow, Z. Sun, R. J. Mattison, et al., "Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults," New England Journal of Medicine 391, no. 4 (2024): 320–333. Google Scholar Early ViewOnline Version of Record before inclusion in an issuee31657 ReferencesRelatedInformation